Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined. METHODS: We prospectively followed a multicenter patient population that included the full histologic spectrum of NAFLD. The incidences of death and other outcomes were compared across baseline histologic characteristics. RESULTS: A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]). The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14). As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages. After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3). CONCLUSIONS: In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; NAFLD DB2 ClinicalTrials.gov number, NCT01030484.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The risk of future liver-related events starts to increase at fi brosis stage 2.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [122]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“fibrosis stage is predictive of liver-specific morbidity and mortality.”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Ultimately, those with NASH and fibrosis may develop end-stage complications such as cirrhosis, portal hypertension or hepatocellular carcinoma (HCC), which portend a much worse prognosis.6–10”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
In the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [261]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationA Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citation
Cited by
Items 301–400 of 1,001
Nonalcoholic fatty liver disease from a primary care perspective
Clark, J. M., Cryer, D. R. H., Morton, M., & Shubrook, J. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15016 · Cited by 27
“ceal haemorrhage, encephalopathy, end-stage liver disease, hepatocellular carcinoma [HCC] and death).(7,8) NAFLD is characterized by chronic inflammation.”
BackgroundSelf-citationȚâru, M.-G., Neamți, L., Țâru, V., Procopciuc, L. M., Procopeț, B., & Lupșor‐Platon, M. (2023) · Diagnostics · doi:10.3390/diagnostics13040788 · Cited by 31
Babiy, B., Ramos‐Molina, B., Ocaña, L., Sacristán, S., Burgos‐Santamaría, D., Martínez-Botas, J., Busto, R., Busto, R., Frutos, M. D., Albillos, A., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2023.159318 · Cited by 25
Population screening for cirrhosis
Thiele, M. S., Pose, E., Juanola, A., Mellinger, J. L., & Ginès, P. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000512 · Cited by 27
“[3,4] The increased global burden of cirrhosis can be ascribed to increases in obesity and type 2 diabetes, continued high per-capita alcohol intake, deficient vaccination, inadequate delivery of HBV, HCV, and AUD treatments, and delayed diagnosis, leading to a lack of preventive measures.”
BackgroundManaging cirrhosis with limited resources: perspectives from sub-Saharan Africa
Sonderup, M. W., Kamath, P. S., Awuku, Y. A., Desalegn, H., Gogela, N. A., Katsidzira, L., Tzeuton, C., Bobat, B., Kassianides, C., & Spearman, C. W. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00279-0 · Cited by 26
US-based Sequential Algorithm Integrating an AI Model for Advanced Liver Fibrosis Screening
Chen, L., Huang, Z.-R., Yang, H., Cheng, M.-Q., Hu, H.-T., Lu, X.-Z., Li, M., Lu, R.-F., He, D.-N., Lin, P., et al. (2024) · Radiology · doi:10.1148/radiol.231461 · Cited by 28
Moving diagnosis of liver fibrosis into the community
Pose, E., Piano, S. S., Thiele, M. S., Fabrellas, N., Tsochatzis, E. A., & Ginès, P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.026 · Cited by 28
Liu, J., Liu, Z., Liu, C., Sun, H. Q., Li, X., & Yang, Y. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70039 · Cited by 31
“The prevalence of NAFLD in patients with MetS is higher than in the general population, with associated risks of liver fibrosis progression and increased CVDs [56].”
Zhu, H., Liu, L., Yang, S., Fu, Y., Pan, Y., Fu, Q., Du, F., & Zhou, X. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03079-2 · Cited by 27
Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis
Hu, Y., Yang, B., Xiao, C., Yang, X., Zhang, H., Yang, P., Du, X., Zhang, G., Liang, B., Bai, N., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.001 · Cited by 32
Enomoto, M., Kaji, K., Nishimura, N., Fujimoto, Y., Murata, K., Takeda, S., Tsuji, Y., Fujinaga, Y., Takaya, H., Kawaratani, H., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.04.012 · Cited by 26
Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target
Chen, H. (2022) · Liver Research · doi:10.1016/j.livres.2022.09.003 · Cited by 27
Identification of high-risk subjects in nonalcoholic fatty liver disease
Stern, C., & Castéra, L. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0431 · Cited by 29
“0 years (total: 8,120 person years) (18).”
Puengel, T., & Tacke, F. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2230115 · Cited by 24
Han, W. M., Apornpong, T., Lwin, H. M. S., Thammapiwan, S., Boonrungsirisap, J., Gatechompol, S., Ubolyam, S., Tangkijvanich, P., Kerr, S. J., & Avihingsanon, A. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad433 · Cited by 24
Wang, A., Blackford, A. L., Behling, C. A., Wilson, L., Newton, K. P., Xanthakos, S. A., Fishbein, M. H., Vos, M. B., Mouzaki, M., Molleston, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000644 · Cited by 24
“[4,5] Although long-term data on outcomes for pediatric NAFLD are limited, it is expected that fibrosis will be an important predictor of adverse outcomes for children as well.”
BackgroundSelf-citationIto, D., Shimizu, S., Haisa, A., Yanagisawa, S., Inoue, K., Saito, D., Sumita, T., Yanagisawa, M., Uchida, Y., Inukai, K., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14246 · Cited by 27
“…chronic liver disease, while metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH) with fi brosis, has emerged as a serious risk factor for liver-related complications, including hepatic decompensation, hepatocellular carcinoma, and death 3 .”
BackgroundMonitoring disease progression in metabolic dysfunction‐associated steatotic liver disease
Noureddin, N., Copur‐Dahi, N., & Loomba, R. S. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17752 · Cited by 40
“30 Ng et al. reported similar findings based on a meta-analysis of 17,301 patients with MASLD.”
ResultSelf-citationMAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD
Chan, W., Wong, V. W., Adams, L. A., & Nguyen, M. H. (2024) · Hepatology International · doi:10.1007/s12072-024-10661-x · Cited by 29
“An increased risk of renal impairment is also associated with MAFLD, especially in the presence of fibrosis [93–95].”
Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD
Schreiner, A. D., Zhang, J., Petz, C. A., Moran, W. P., Koch, D. G., Marsden, J. E., Bays, C., Mauldin, P. D., & Gebregziabher, M. (2024) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2024-001404 · Cited by 26
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 25
“[56,57] Thus, sustained weight loss is crucial for reducing liver-related morbidity and mortality in SLD.”
BackgroundGenetic and non-genetic drivers of histological progression and regression in MASLD
Gómez, E. V., Yates, K. P., Kleiner, D. E., Behling, C. A., Cummings, O. W., Wilson, L., Liang, T., Jarasvaraparn, C., Loomba, R., Schwimmer, J. B., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.09.013 · Cited by 29
Self-citationMarjot, T., Smith, K., Westcott, F., White, S., Johnson, E. M., Srnic, N., Barrett, A., Hall, E., Gralton, K., Dennis, K. M. J. H., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.12.004 · Cited by 30
Pryke, R., & Guha, I. N. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.010 · Cited by 25
Wong, Y. J., Urias, E., Song, M. W., Goyal, T., Tay, W. X., Han, N. X., Loo, J. H., Qiu, T. Y., Wijarnpreecha, K., Chan, Y. H., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000244 · Cited by 24
Advancements in MAFLD Modeling with Human Cell and Organoid Models
Wang, S.-X., Yan, J.-S., & Chan, Y.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911850 · Cited by 22
“Patients with MAFLD and more severe liver fibrosis (stages F3 and F4 or cirrhosis) have an estimated higher risk of liver-related complications and deaths compared with the control group (fibrosis stages F0 to F2) [5,10].”
BackgroundPecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 29
Balkhed, W., Bergram, M., Iredahl, F., Holmberg, M., Edin, C., Carlhäll, C., Ebbers, T., Henriksson, P., Simonsson, C., Rådholm, K., et al. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20103 · Cited by 26
Dissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics
Colella, F., Henderson, N. C., & Ramachandran, P. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186421 · Cited by 31
“Series Editor: Scott L. Friedman”
Bajaj, J. S., Rodríguez, M. P., Reau, A. L., Phillips, W., Fuchs, M. A., Davis, B., Sterling, R. K., Sikaroodi, M., Fagan, A., Shamsaddini, A., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-328403 · Cited by 23
Wang, X., Moore, M. P., Shi, H., Miyata, Y., Donnelly, S. K., Radiloff, D. R., & Tabas, I. (2023) · Molecular Therapy Methods & Clinical Development · doi:10.1016/j.omtm.2023.101165 · Cited by 21
Noninvasive Quantitative CT for Diffuse Liver Diseases: Steatosis, Iron Overload, and Fibrosis
Pickhardt, P. J., & Lubner, M. G. (2024) · Radiographics · doi:10.1148/rg.240176 · Cited by 27
Luthra, R., & Sheth, A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03085-4 · Cited by 23
Brennan, P., Kopka, C. J., Agirre‐Garrido, L., Hansen, C. D., Alkhouri, N., Schattenberg, J. M., Wajcman, D. I., Isaacs, S. D., Michel, M. S., & Lazarus, J. V. (2025) · npj gut and liver. · doi:10.1038/s44355-024-00017-5 · Cited by 25
“The natural historyofMASLDandMASHdemonstratesthatasliver fi brosisprogresses, the incidence of both liver events, including progression to cirrhosis and hepatocellular carcinoma (HCC), and extrahepatic events such as cardio-vascular complications and non-liver cancer increase 2 .”
Alkhouri, N., Yip, T. C., Castéra, L., Takawy, M., Adams, L. A., Verma, N., Arab, J. P., Jafri, S., Zhong, B., Dubourg, J., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003432 · Cited by 33
“Patients with signi fi cant fi brosis or higher ( $ F2) because of MASH are at an increased risk of progression and morbidity (4) and may bene fi t from newly approved resmetirom treatments (13).”
NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?
Chen, B. Y., Tang, W. H. W., Rodriguez, M., Corey, K. E., Sanyal, A. J., Kamath, P. S., Bozkurt, B., Virk, H. U. H., Pressman, G. S., Lazarus, J. V., et al. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1757712 · Cited by 24
Self-citationChan, W. L., Chong, S.-E., Chang, F. W. S., Lai, L. L., Chuah, K. H., Mustapha, N. R. N., Mahadeva, S., & Chan, W. (2023) · Hepatology International · doi:10.1007/s12072-023-10550-9 · Cited by 25
“This exponential increase in cumulative incidence of liver-related events is similar to that observed by Sanyal and colleagues [26], with the cumulative incidence being 0.”
ResultInfluentialPennisi, G., Enea, M., Romero‐Gómez, M., Bugianesi, E., Wong, V. W., Fracanzani, A. L., de Lédinghen, V., George, J., Berzigotti, A., Viganò, M., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000616 · Cited by 22
“[4,10,14] However, when looking at natural history studies in MASLD, some reports have also observed fibrosis progression also in patients without MASH, [15] supporting a role for fibrosis, regardless of the presence of steatohepatitis, in driving liver-related and extrahepatic outcomes.”
BackgroundKobayashi, T., Iwaki, M., Nogami, A., Kawamura, N., Honda, Y., Ogawa, Y., Imajo, K., Yoneda, M., Saito, S., & Nakajima, A. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02049-9 · Cited by 28
“Large prospective studies and meta-analyses have found that fibrosis stage ≥ 2 or ≥ 3 is associated with an increased incidence of liver-related and all-cause mortality [6, 8].”
BackgroundAir pollution associate with advanced hepatic fibrosis among patients with chronic liver disease
Jang, T., Ho, C.-C., Liang, P., Wu, C., Wei, Y., Tsai, P., Hsu, P., Hsieh, M., Lin, Y., Hsieh, M., et al. (2023) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12781 · Cited by 24
Park, H., Yoon, E. L., Kim, M., Kwon, S., Kim, D., Cheung, R. C., Kim, H., & Jun, D. W. (2024) · Liver International · doi:10.1111/liv.15838 · Cited by 26
“27,32 Recognising NAFLD as a multi-organ disease, it becomes crucial to emphasize the societal burden intertwined with cardiovascular disease, in tandem with the progression of liver disease.”
BackgroundȚâru, M.-G., Tefas, C., Neamți, L., Minciună, I., Țâru, V., Maniu, A., Rusu, I., Petrushev, B., Procopciuc, L. M., Leucuta, D., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303971 · Cited by 24
“Liver fibrosis is a crucial determinant of prognosis in patients with MASLD [3], leading to a significant rise in overall mortality and increased risk of developing liver-related events (LREs), especially among patients with advanced fibrosis ( � F3) or cirrhosis (F4) [4].”
BackgroundWang, Y., Wu, Y., Zhang, H., Wang, J., Song, A., Qiu, H., Yuan, X., Xiong, H., & Zou, Y. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000064 · Cited by 23
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
Geng, W., Liao, W., Cao, X., & Yang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13020393 · Cited by 20
“In contrast, NASH is marked by hepatocyte ballooning degeneration, diffuse lobular inflammation, and a higher risk of progressing to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [4].”
Vidal-Trécan, T., Julla, J., Khoury, T. E., Venteclef, N., Riveline, J., Paradis, V., Valla, D. C., Gautier, J., & Castéra, L. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.02.018 · Cited by 29
TREM2 in MASH: integrating lipid metabolism and immune response
Shi, S., Zhou, Y. Y., Zhang, H., & Zhang, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604837 · Cited by 28
Value-Based Pricing of Resmetirom for Metabolic Dysfunction–Associated Steatotic Liver Disease
Le, P. N. B., Dasarathy, S., Herman, W. H., Adekunle, O. A., Tran, H. T., Criswell, V., Ye, W., Welch, N., Yue, Y., & Rothberg, M. B. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17122 · Cited by 23
Self-citationNielsen, M. J., Dolman, G. E., Harris, R., Frederiksen, P., Chalmers, J., Grove, J. I., Irving, W. L., Karsdal, M. A., Patel, K., Leeming, D. J., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100743 · Cited by 26
Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease
Ishido, S., Tamaki, N., Takahashi, Y., Uchihara, N., Suzuki, K., Tanaka, Y., Miyamoto, H., Yamada, M., Matsumoto, H., Nobusawa, T., et al. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02848-7 · Cited by 23
Zhang, F., Han, Y., Wu, Y., Bao, Z., Zheng, G., Liu, J., & Li, W. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2409342 · Cited by 21
“Patients with Nash, particularly those with high histologic activity and fibrosis staging of 2 or higher, experience a significant increase in liver-related events and mortality [5].”
BackgroundTincopa, M. A., Díaz, L. A., Huang, D. Q., Arab, J. P., Arrese, M. A., Gadano, A., de Oliveira, C. P. M. S., Bettencourt, R., Madamba, E. V., Kim, S., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001121 · Cited by 25
Self-citationMichel, M. S., Labenz, C., Anders, M., Wahl, A., Girolstein, L., Kaps, L., Kremer, W. M., Huber, Y., Galle, P. R., Sprinzl, M. F., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1958 · Cited by 22
Tsutsumi, T., Kawaguchi, T., Fujii, H., Kamada, Y., Takahashi, H., Kawanaka, M., Sumida, Y., Iwaki, M., Hayashi, H., Toyoda, H., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17995 · Cited by 21
“(Figure S1) Similarly, in the study by Sanyal et al, 30 the cumulative rates at 5 and 10 years of follow-up were approximately 0.02 and 0.03 for F0–2 and 0.04 and 0.12 for F3, respectively.”
ResultInfluentialDíaz, L. A., Tavaglione, F., Mittal, N., Bettencourt, R., Amangurbanova, M., Johnson, A., Aguado, D. M., Tincopa, M. A., Loomba, R. K., Khan-Riches, A., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000718 · Cited by 25
“Liver fibrosis, particularly advanced fibrosis and cirrhosis, is the main predictor of liver-related death in individuals with SLD. [10,24] In our study, 4 individuals with suspected MetALD had significant fibrosis, 3 advanced fibrosis, and 1 cirrhosis, representing a prevalence of 8% of at least…”
Self-citationScreening for advanced steatotic liver disease
Johansen, S., Åberg, F. O., Tsochatzis, E. A., & Krag, A. A. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00097-4 · Cited by 20
The Chromatin Accessibility Landscape of Nonalcoholic Fatty Liver Disease Progression
Kang, B., Kang, B., Roh, T., Seong, R. H., & Kim, W. K. (2022) · Molecules and Cells · doi:10.14348/molcells.2022.0001 · Cited by 20
“Liver histology was assessed using the NASH Clinical Research Network (CRN) histological scoring system (Sanyal et al., 2021).”
MethodInamine, S., Kage, M., Akiba, J., Kawaguchi, T., Yoshio, S., Kawaguchi, M., Nakano, D., Tsutsumi, T., Hashida, R., & Oshiro, K. (2022) · Hepatology Research · doi:10.1111/hepr.13808 · Cited by 23
“In patients with fatty liver, hepatic fibrosis has been recognized as a factor associated with poor prognosis.(5) Reportedly, 35.”
BackgroundSanyal, A. J., Muñoz, B., Cusi, K. J., Barritt, A. S., Muthiah, M. D., Mospan, A. R., Reddy, K. R., Firpi-Morell, R. J., Thuluvath, P. J., Bhamidimarri, K. R., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.024 · Cited by 24
Self-citationA View on Drug Development for Cancer Prevention
Reynolds, A. R., Moschetta, M., Yohannes, A. R., Walcott, F. L., Ashford, M. B., Szűcs, Z., Sarbajna, T., Hadfield, J., Harrison, E., Challis, B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0776 · Cited by 21
Miller, M. J., Harding-Theobald, E. R., DiBattista, J. V., Zhao, Z., Wijarnpreecha, K., Lok, A. S.-F., & Chen, V. L. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000148 · Cited by 20
“[7–9] While NAFLD can progress to decompensated cirrhosis and is projected to become the leading indication for liver transplantation in the US,[10,11] only a minority of patients with NAFLD ultimately develop cirrhosis.[12,13] Identifying the subset of NAFLD patients who will progress to advanced fibrosis or cirrhosi…”
BackgroundInfluentialMiura, K., Hayashi, H., Kamada, Y., Fujii, H., Takahashi, H., Oeda, S., Iwaki, M., Kawaguchi, T., Tomita, E., Yoneda, M., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13938 · Cited by 20
Koutoukidis, D. A., Mózes, F. E., Jebb, S. A., Tomlinson, J., Pavlides, M., Saffioti, F., Huntriss, R., Aveyard, P. N., & Cobbold, J. (2023) · Obesity · doi:10.1002/oby.23793 · Cited by 20
“increases the burden on both patients and health care systems [2, 3].”
BackgroundNabi, O., Lapidus, N., Boursier, J., de Lédinghen, V., Kab, S., Renuy, A., Zins, M., Serfaty, L., & Lacombe, K. (2023) · Liver International · doi:10.1111/liv.15674 · Cited by 19
Custodio, R. J. P., Hobloss, Z., Myllys, M., Hassan, R. A. R. A., González, D., Reinders, J., Bornhorst, J., Weishaupt, A.-K., Seddek, A., Abbas, T., et al. (2023) · Cells · doi:10.3390/cells12182331 · Cited by 21
“Furthermore, a prospective study of 1773 adults with MASLD identified HE and ascites as the most common hepato-related decompensation events [12].”
BackgroundMicroRNAs and Nonalcoholic Steatohepatitis: A Review
Morishita, A., Oura, K., Tadokoro, T., Fujita, K., Tani, J., Kobara, H., Ono, M., Himoto, T., & Masaki, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914482 · Cited by 21
“A clinical prospective study reported by the NASH Clinical Research Network (CRN) found that cases with advanced fibrosis due to NASH progression were associated with a significantly increased incidence of hepatocellular carcinoma and complications, including liver-related death [11].”
BackgroundThrombospondin 2 is a key determinant of fibrogenesis in non‐alcoholic fatty liver disease
Kimura, T., Iwadare, T., Wakabayashi, S., Kuldeep, S., Nakajima, T., Yamazaki, T., Aomura, D., Zafar, H., Iwaya, M., Joshita, S., et al. (2023) · Liver International · doi:10.1111/liv.15792 · Cited by 22
“4 7 However, the mechanisms underlying the progression of liver fibrosis are not fully understood, and effective therapeutic strategies for NAFLD have yet to be established.”
BackgroundWang, H., Liu, Z., Fan, H. X., Guo, C., Zhang, X., Li, Y., Han, X., & Zhang, T. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105477 · Cited by 21
Optimizing liver health before and after gene therapy for hemophilia A
Ragni, M. V., Mead, H., de Jong, Y. P., Kaczmarek, R., Leavitt, A. D., Long, B. R., Nugent, D. J., Sabatino, D. E., Fong, S., von Drygalski, A., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013059 · Cited by 20
“19,21,36 A subset of patients with MASLD develop steatohepatitis (metabolic dysfunction – associated steatohepatitis, formerly nonalcoholic steatohepatitis), which is characterized by in fl ammation and hepatocyte proliferation, and is a major risk factor for HCC in the general population and people…”
BackgroundLongitudinal Evaluation of Individuals With Severe Alpha-1 Antitrypsin Deficiency (Pi∗ZZ Genotype)
Fromme, M., Payancé, A., Mandorfer, M., Thorhauge, K. H., Pons, M., Miravitlles, M., Stolk, J. N., van Hoek, B., Stirnimann, G., Fraňková, S., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.10.010 · Cited by 20
When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD
Rojano‐Toimil, A., Rivera‐Esteban, J., Manzano-Núñez, R., Bañares, J., Selva, D. M., Gabriel-Medina, P., Ferrer, R., Pericàs, J. M., & Ciudin, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123286 · Cited by 22
“The spectrum of the disease ranges from mild hepatic steatosis and liver inflammation (non-alcoholic steatohepatitis or NASH) to liver fibrosis and cirrhosis that lead to liver-related events and increased overall mortality [2].”
BackgroundTheel, W. B., Klerk, B. M. B., Dirksmeier-Harinck, F., van Rossum, E. F. C., Kanhai, D. A., Apers, J. A., van Dalen, B. M., de Knegt, R. J., Holleboom, A. G., Tushuizen, M. E., et al. (2022) · Obesity Reviews · doi:10.1111/obr.13481 · Cited by 22
“27 29 – 32 Patients with NASH often have multiple cardiovascular risk factors which generally determine the main cause of death.”
BackgroundTong, X., Song, Y., Yin, S., Wang, J., Huang, R., Wu, C., Shi, J., & Li, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002310 · Cited by 23
“In developed countries, NAFLD could account for >30% of HCC cases.([5]) As we know, CHB infection is an important cause of HCC formation, and previously, >70% of the HCC incidence was attributed to chronic viral hepatitis.”
BackgroundInfluentialBadal, B. D., & Bajaj, J. S. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.01.003 · Cited by 19
FIB-4 Reliability in Patients With Severe Obesity: Lower Cutoffs Needed?
Green, V., Lin, J., McGrath, M., Lloyd, A., Ma, P., Higa, K. D., & Roytman, M. M. (2023) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001937 · Cited by 19
“14 Furthermore, as treatments targeting MASH emerge, there is a greater emphasis on accurate and early staging of fi brosis.”
Larson, E. L., Ellias, S. D., Blezek, D. J., Klug, J., Hartman, R. P., Francisco‐Ziller, N., Bamlet, H., Mao, S. A., Perry, D. K., Nimma, I. R., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.030 · Cited by 20
Call to action—Pediatric MASLD requires immediate attention to curb health crisis
Hartmann, P., Mouzaki, M., Hassan, S. M., Kehar, M., Mysore, K. R., Mauney, E. E., Nonga, D., Karjoo, S., Sood, S., Tou, A. M., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001440 · Cited by 20
Self-citationChoo, B. P., Goh, G. B., Chia, S. Y., Oh, H. C., Tan, N. C., Tan, J. Y. L., Ang, T. L., Bee, Y. M., & Wong, Y. J. (2022) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2022284 · Cited by 18
Kugelmas, M., Noureddin, M., Gunn, N., Brown, K., Younossi, Z. M., Abdelmalek, M. F., & Alkhouri, N. (2023) · Liver International · doi:10.1111/liv.15555 · Cited by 21
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
Agyapong, G., Dashti, F., & Banini, B. A. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15012 · Cited by 19
Martínez‐Urbistondo, D., Pérez-Díaz-del-Campo, N., Landecho, M. F., & Martínez, J. A. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00560-5 · Cited by 24
“Both simple steatosis and stea-tohepatitis have been shown to influence the overall outcome of patients, although hepatic fibrosis is the marker most associated with morbidity in this population [96].”
BackgroundChouik, Y., Aubin, A., Maynard, M., Segrestin, B., Milot, L. M., Hervieu, V., Zoulim, F., Disse, E., Levrero, M., & Caussy, C. (2024) · Obesity · doi:10.1002/oby.24033 · Cited by 20
“The most critical determinant of overall prognosis and liver-related outcomes is the fibrosis stage, with a 1.9-to 3.9-fold increase in all-cause mortality in patients with advanced fibrosis (AF; i.e., F3-F4) compared with others [4].”
BackgroundInfluentialYan, C., Zhang, W., Xiao, Y., Sun, Y., Peng, X., & Cai, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1376894 · Cited by 19
Adinolfi, L. E., Marrone, A., Rinaldi, L., Nevola, R., Izzi, A., & Sasso, F. C. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001281 · Cited by 19
Tacke, F., Klinker, H., Boeker, K. H. W., Merle, U., Link, R., Buggisch, P., Hüppe, D., Cornberg, M., Sarrazin, C., Wedemeyer, H. H., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2015 · Cited by 21
“, cardiovascular) morbidity and mortality.[20] In addition, HCV is known to contribute to steatosis development and metabolic liver disease[21] by inducing hepatic lipogenesis (which favors indirectly HCV lipoviroparticle assembly),[22] affecting lipoprotein synthesis[23] and fatty acid oxidation in mitochondria.”
BackgroundMare, R. G., & Sporea, I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175223 · Cited by 20
“Over the years, in the absence of histology, the presence of NASH was considered when patients had increased levels of transaminases, but recent studies have shown that approximately 56% of individuals with histologically proven NASH have normal liver enzymes [53,54].”
BackgroundRole of regulatory T cells in inflammatory liver diseases
Yang, L., & Zheng, S. G. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103806 · Cited by 19
Tapper, E. B., Zhao, Z., Mazumder, N. R., & Parikh, N. D. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07454-3 · Cited by 18
“Further, a recent study from the NASH clinical research network showed that HE, not ascites is the most common first complication [25].”
BackgroundSong, Q., Ling, Q., Fan, L., Deng, Y., Gao, Q., Yang, R., Chen, S., Wu, S., & Cai, J. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002111 · Cited by 17
“6-year follow-up inpatients withNAFLD found a borderline significantly increased risk of hypertension.([28]) NAFLDwas diagnosed pathologically, the gold standard, which enhanced the strength of this finding.”
BackgroundNonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
Yoneda, M., Kobayashi, T., Iwaki, M., Nogami, A., Saito, S., & Nakajima, A. (2023) · Gut and Liver · doi:10.5009/gnl220545 · Cited by 19
“8 Also, 7-ketocholesterol, an oxidized form of cholesterol produced by freezing and cooking of foods and present in processed foods, has been associated with the development of CVD and hepatic steatosis.”
BackgroundBoursier, J., Roux, M., Costentin, C. E., Chaigneau, J., Fournier, C., Trylesinski, A., Canivet, C. M., Michalak, S., Bail, B. L., Paradis, V., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40328-4 · Cited by 19
“The prognosis for patients with non-alcoholic fatty liver disease (NAFLD), the most prevalent cause of chronic liver disease worldwide, is closely linked to their stage of liver fi brosis 1,2 .”
BackgroundRole of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 21
“19 20 The fourth goal extends beyond liver health to reduce cardiometabolic mortality in patients with MASLD, acknowledging the strong link between liver health and cardiovascular risk and addressing the patient’s overall health profile.”
Mathur, A., Ozkaya, E., Rosberger, S., Sigel, K. M., Doucette, J. T., Bansal, M. B., & Taouli, B. A. (2025) · European Radiology · doi:10.1007/s00330-025-11533-0 · Cited by 18
Ratziu, V., Anstee, Q. M., Wong, V. W., Schattenberg, J. M., Bugianesi, E., Augustín, S., Gheorghe, L. S., Azevedo, V. Z., & Reau, N. S. (2022) · Hepatology · doi:10.1002/hep.32500 · Cited by 18
“This stands in contrast with the slowly evolving course of this disease[12,13] and may account for the high level of medical expenditures documented in some real- world administrative claims databases.”
ResultRisk-stratified hepatocellular carcinoma surveillance in non-cirrhotic patients with MASLD
Mi, K., Ye, T., Zhu, L., & Pan, C. Q. (2025) · Gastroenterology report · doi:10.1093/gastro/goaf018 · Cited by 22
Neuschwander‐Tetri, B. A., Akbary, K., Carpenter, D. H., Noureddin, M., & Alkhouri, N. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.04.026 · Cited by 18
Self-citationAceituno, L., Bañares, J., Pons, M., Rivera‐Esteban, J., Sabiote, C., Cammà, C., Ciancimino, G., Pennisi, G., Tulone, A., Ma, M. M., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.08.020 · Cited by 21
Is liver steatosis a disease or the emperor’s new clothes?
Krag, A. A., Tacke, F., Israelsen, M. E., & Younossi, Z. M. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2025.12.026 · Cited by 18
Grocic, M., Nguyen, M., & Sanyal, A. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70662 · Cited by 19
Self-citationOkanoue, T., Yamaguchi, K., Shima, T., Mitsumoto, Y., Mizuno, M., Katayama, T., Seko, Y., Moriguchi, M., Umemura, A., Itoh, Y., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13826 · Cited by 16
“The NASH CRN recently reported that there were only 9 cases of new‐onset HCC during the 4‐year follow‐up period in 1773 NAFLD cases, including 369 F3 and 167 F4 cases.(37) A recent cohort study in 1398 biopsy‐proven Japanese NAFLD patients reported that HCC incidence was 4.”
ResultZhan, H., Chen, S., Gao, F., Wang, G., Chen, S., Xi, G., Yuan, H., Li, X., Liu, W., Byrne, C. D., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17635 · Cited by 19
Metadata
- Authors
- Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., Wilson, L. A., Yates, K. P., Belt, P., Lazo, M., Kleiner, D. E., Behling, C., & Tonascia, J.
- Affiliations
- National Institutes of Health (US)
- From the Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); the Bloomberg School of Public Health, Johns Hopkins University, Baltimore (M.L.V.N., J.C., L.A.W., K.P.Y., P.B., M.L., J.T.), and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda (D.E.K.) — both in Maryland; Saint Louis University, St. Louis (B.A.N.-T.); Duke University, Durham, NC (A.M.D.); Cleveland Clinic, Cleveland (S.D.); the University of California, San Diego, School of Medicine, La Jolla (R.L., C.B.), and the University of California, San Francisco, School of Medicine, San Francisco (B.H.); Indiana University School of Medicine, Indianapolis (N.C.); and the Liver Institute Northwest, Seattle (K.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1559-1569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8881985
- OpenAlex
- W3206948891
- Cited by
- 1,146
- References
- 29
- Citations by year
- 2026: 215 · 2025: 270 · 2024: 266 · 2023: 236 · 2022: 153 · 2021: 3
- FWCI
- 118.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061713, U01DK061718, U01DK061728, U01DK061731)
- National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, all-cause mortality, liver complications, hepatic decompensation, variceal bleeding, ascites, hepatic encephalopathy, hepatocellular carcinoma, liver cirrhosis, bridging fibrosis, type 2 diabetes, estimated glomerular filtration rate, cardiac events, prognosis
- MeSH terms
- Adult, Biopsy, Female, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, Incidence, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.